Paper26322834
Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2.
Ribeiro L and 22 others. Invest Ophthalmol Vis Sci, 2015. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2. Papers, record 26322834. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26322834
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Diabetic Retinopathy | Major topic |
| Retina | Major topic |
| Tomography, Optical Coherence | Major topic |
| Visual Acuity | Major topic |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Disease Progression | |
| Follow-Up Studies | |
| Prognosis | |
| Prospective Studies | |
| Time Factors |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01145599 | Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures | Derived from the trial | Yes |
Source ClinicalTrials.gov
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39061684 | Distribution of Microaneurysms and Hemorrhages in Accordance with the Grading of Diabetic Retinopathy in Type Diabetes Patients. | Diagnostics (Basel) | 2024 | https://conductscience.org/library/papers/39061684 | PubMed |
| 36495395 | Different Risk Profiles for Progression of Nonproliferative Diabetic Retinopathy: A 2-Year Study. | Ophthalmol Ther | 2023 | https://conductscience.org/library/papers/36495395 | PubMed |
| 35241519 | In Vivo Imaging of Ischemia/Reperfusion-mediated Aminopeptidase N Expression in Surgical Rat Model Using 68Ga-NOTA-c(NGR). | In Vivo | 2022 | https://conductscience.org/library/papers/35241519 | PubMed |
| 34865186 | Characterization of One-Year Progression of Risk Phenotypes of Diabetic Retinopathy. | Ophthalmol Ther | 2022 | https://conductscience.org/library/papers/34865186 | PubMed |
| 32408522 | Retinopathy Phenotypes in Type 2 Diabetes with Different Risks for Macular Edema and Proliferative Retinopathy. | J Clin Med | 2020 | https://conductscience.org/library/papers/32408522 | PubMed |
| 30120928 | Correlation of spectral domain optical coherence tomography with histology and electron microscopy in the porcine retina. | Exp Eye Res | 2018 | https://conductscience.org/library/papers/30120928 | PubMed |
| 29896271 | MicroRNA-27a protects retinal pigment epithelial cells under high glucose conditions by targeting TLR4. | Exp Ther Med | 2018 | https://conductscience.org/library/papers/29896271 | PubMed |
| 28539797 | Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy: current status and future prospects. | Eye Brain | 2016 | https://conductscience.org/library/papers/28539797 | PubMed |
| 27847629 | Human retinal microvascular imaging using adaptive optics scanning light ophthalmoscopy. | Int J Retina Vitreous | 2016 | https://conductscience.org/library/papers/27847629 | PubMed |
| 27344955 | Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice. | Exp Eye Res | 2016 | https://conductscience.org/library/papers/27344955 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26322834
GET https://conductscience.org/api/papers/v1/26322834/authors?page=2